

3 October 2006

## **Seminar by Dr C. Frank Bennett at Bio21 Auditorium, Monday 9<sup>th</sup> October 2006**

Antisense Therapeutics Limited (ASX: ANP) is hosting a visit to Australia by Dr C. Frank Bennett, Senior V.P. of Research at Isis Pharmaceuticals Inc (Isis). As the first company to successfully bring an antisense drug to the market (Vitravene<sup>®</sup>), Isis is the world's leading clinical RNA-based therapeutics company. One of the founding members of Isis, Dr Bennett is recognised as an international leader in the pharmacology of RNA-targeting drugs, and he was recently appointed to the Board of Directors at Antisense Therapeutics. Isis is Antisense Therapeutics' key strategic technology partner and major shareholder.

As part of his visit, Dr. Bennett will be delivering a one-hour seminar at the Bio21 Institute in Parkville, Melbourne on Monday 9<sup>th</sup> October at 4 pm. His seminar will range from the underlying theory and biology of antisense gene targeting to clinical trial progress in Isis' latest antisense drugs. It will be attended by prominent medical researchers from surrounding, world-class institutes in the Parkville medical biotechnology precinct.

Dr Bennett's seminar will provide insights into how Isis is translating the power of RNA silencing into medicines in clinical practice. This is illustrated by research and clinical data on Isis' 2<sup>nd</sup> generation antisense cholesterol-lowering drug, ISIS 301012. Interest in RNA-silencing drugs has intensified in recent years, and Dr Bennett's presentation will highlight how the industry leaders believe oligonucleotide therapeutics will be positioned amongst novel medicines in the immediate future.

The Bio21 Institute is a commercially focused hub and incubator for translational R&D in Melbourne.

### ***About Antisense Therapeutics Limited***

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise novel antisense pharmaceuticals for large unmet markets. ANP's major shareholders include Circadian Technologies Limited (ASX: CIR) and Isis Pharmaceuticals Inc (NASDAQ: ISIS).

#### *Contact Information:*

Website: [www.antisense.com.au](http://www.antisense.com.au)

Managing Director – Mark Diamond +61 3 9827 8999

Company Secretary – Kathryn Andrews +61 3 9827 8999

Media – Market Connect (Simon Watkin) +61 3 9686 9931